CR8251A - Composiciones de hiv inmunogenicas y metodos relacionados - Google Patents

Composiciones de hiv inmunogenicas y metodos relacionados

Info

Publication number
CR8251A
CR8251A CR8251A CR8251A CR8251A CR 8251 A CR8251 A CR 8251A CR 8251 A CR8251 A CR 8251A CR 8251 A CR8251 A CR 8251A CR 8251 A CR8251 A CR 8251A
Authority
CR
Costa Rica
Prior art keywords
immunogenic compositions
hiv
antigen
related methods
hiv antigen
Prior art date
Application number
CR8251A
Other languages
English (en)
Inventor
B Moss Ronald
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of CR8251A publication Critical patent/CR8251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invencion proporciona composiciones inmunogenicas que mejoran la duracion y resistencia de la respuesta inmune en un mamifero. Las composiciones inmunogenicas continen un antigeno HIV, un inmunomero y un adyuvante. El antigeno HIV puede ser un virus HIV exterminado completo exento de proteina envolvente externa gp120. Alternativamente, el antigeno HIV puede ser un virus HIV exterminado completo. O un antigeno p24. Tambien se proporcionan equipos, los componentes de los cuales, cuando se combinan, producen las composiciones inmunogenicas de la invencion. La invencion tambien proporciona metodos para hacer las composiciones inmunogenicas, combinando un antigeno HIV, un inmunomero y opcionalmente un adyuvante.
CR8251A 2003-08-28 2006-02-22 Composiciones de hiv inmunogenicas y metodos relacionados CR8251A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49880403P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
CR8251A true CR8251A (es) 2008-09-23

Family

ID=34272731

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8251A CR8251A (es) 2003-08-28 2006-02-22 Composiciones de hiv inmunogenicas y metodos relacionados

Country Status (14)

Country Link
US (2) US20070253979A1 (es)
EP (1) EP1670893A4 (es)
JP (1) JP2007523884A (es)
CN (1) CN101291691A (es)
AP (1) AP2006003530A0 (es)
AU (1) AU2004269379A1 (es)
BR (1) BRPI0413906A (es)
CA (1) CA2535527A1 (es)
CR (1) CR8251A (es)
IL (1) IL173740A0 (es)
MX (1) MXPA06001996A (es)
OA (1) OA13246A (es)
WO (1) WO2005021726A2 (es)
ZA (1) ZA200602246B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
CN101217973A (zh) * 2004-03-12 2008-07-09 海布里顿公司 使用第二代免疫调节寡核苷酸增强的hiv疫苗活性
EP2344143A1 (en) 2008-09-09 2011-07-20 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
DK2575878T3 (en) * 2010-05-28 2018-08-13 Zoetis Belgium S A VACCINES INCLUDING CHOLESTEROL AND CPG AS THE ONLY ADJUVENT CARRIER MOLECULES
EP3173096A1 (en) * 2011-04-06 2017-05-31 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
CN103732248B (zh) * 2011-04-06 2018-08-28 拜欧瓦克西姆有限公司 用于预防和/或治疗人中的hiv疾病的药物组合物
JP6557240B2 (ja) 2014-01-08 2019-08-07 イミュノバティブ セラピーズ，リミテッド ヒト免疫不全ウイルス／後天性免疫不全症候群の治療
TWI714529B (zh) * 2015-05-20 2021-01-01 以色列商梵提夫免疫療法公司 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010323A (pt) * 1999-05-06 2002-01-08 Immune Response Corp Inc Composições imunogênicas, kit e método de confecção da mesma para uso na imunização de um mamìfero
BR0206775A (pt) * 2001-01-26 2006-01-17 Immune Response Corp Inc Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.

Also Published As

Publication number Publication date
CN101291691A (zh) 2008-10-22
BRPI0413906A (pt) 2006-10-24
AU2004269379A1 (en) 2005-03-10
WO2005021726A3 (en) 2008-01-17
WO2005021726A2 (en) 2005-03-10
MXPA06001996A (es) 2006-06-20
AU2004269379A2 (en) 2005-03-10
AP2006003530A0 (en) 2006-02-28
US20050196411A1 (en) 2005-09-08
CA2535527A1 (en) 2005-03-10
JP2007523884A (ja) 2007-08-23
US20070253979A1 (en) 2007-11-01
IL173740A0 (en) 2006-07-05
EP1670893A4 (en) 2008-09-03
ZA200602246B (en) 2007-05-30
EP1670893A2 (en) 2006-06-21
OA13246A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
CR8251A (es) Composiciones de hiv inmunogenicas y metodos relacionados
DK1635863T3 (da) Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
AR080216A2 (es) Composiciones farmaceuticas que contienen una proteina de fusion de vih
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
EA200700904A1 (ru) Вакцины против вируса японского энцефалита и вируса западного нила
ATE331530T1 (de) Proteasom-influenzavirus-impfstoffzusammensetzu g
CY1115308T1 (el) Συνθεσεις εμβολιου οι οποιες περιεχουν ανοσοενισχυτικο εκδοχο σαπωνινης
CY1116506T1 (el) Αντισωματα εναντι masp-2
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
HN2001000027A (es) Derivados de purina
CR6491A (es) Composiciones y metodos inmunogenicos de hiv
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
DK1545597T3 (da) Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
DK1401489T4 (da) Solubilisering af kapselpolysaccharid
DK1524993T3 (da) Neisseria-vaccinesammensætning omfattende en kombination af antigener
CY1112879T1 (el) Συνθεση εμβολιου
ATE491467T1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
GT200200133A (es) Formulaciones de latex libres de aceleradores, metodos para hacer dichas formulaciones y articulos hechos de los mismos
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
BR0306905A (pt) Vacinas de flavivìrus
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
BR0108210A (pt) Vacina contra o vìrus da imunodeficiência humana
AR048534A1 (es) Formulaciones de acetato de bazedoxifeno
AR023535A1 (es) Nuevas composiciones.
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)